A Pilot Study of the Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making

The Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making About Antihypertensive Medication: A Pilot Study

This is a randomized pilot study comparing the impact of the Patient Activated Learning System (PALS) on knowledge acquisition, recall, and decision making about antihypertensive medication compared to an established online health information system (WebMD). We will also compare the two systems with regard to user experience measures such as understandability and trust.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Primary research question:

1)Do hypertensive participants who learn about hypertension medication with PALS (intervention) have higher immediate and 1 week knowledge assessment scores than participants randomized to learn the same information via WebMD (control)? The investigators hypothesize that participants in the PALS group will have higher immediate and one week assessment scores.

Secondary research questions:

  1. Do participants in the PALS group feel more informed to make hypothetical decisions about taking medications compared to participants in the WebMD group?

    The investigators hypothesize that participants in the PALS group will be more likely to indicate that they have sufficient information to make hypothetical decisions about taking medications than participants in the WebMD group.

  2. Do participants in the PALS group rate it higher on user experience measures such as trust, usefulness, comprehensibility, and adequacy of the information, attractiveness of the site, and level of engagement, than those in the WebMD group? The investigators hypothesize ratings on these measures will be higher in the PALS group compared to the WebMD group.
  3. Which questions about antihypertensives do participants consider most important and are the 5 most highly rated questions more likely to be addressed on PALS vs. WebMD? The investigators hypothesize that PALS will address more questions that participants rate as important compared to WebMD.

Participants with hypertension, who have been prescribed any antihypertensive medicine except chlorthalidone will be recruited from the Weill Cornell Internal Medicine Associates (WCIMA) practice. Potentially eligible participants who have an upcoming appointment at WCIMA will be identified via a review of the electronic medical record. In cases where the participant's eligibility is unclear, Research Assistants (RA's) will contact the participant's Primary Medical Doctor (PMD) to confirm eligibility. Potentially eligible participants will be contacted via the telephone to assess their interest in participating and to schedule a study visit for those interested. Verbal consent will be obtained either on the phone or at the study visit. Potentially eligible participants may also be recruited from the waiting room at WCIMA if the RA's were unable to contact them by phone prior to their WCIMA visit.

Eligible participants who agree to participate will be randomized to view information about the antihypertensive, chlorthalidone, via the PALS or WebMD. The study procedures will be identical for both the PALS and WebMD groups.

Chlorthalidone was chosen because, despite its efficacy, it is not prescribed as often as other antihypertensives. This will allow the investigators to select a sample of participants who are less likely to have baseline knowledge of the information we are testing.

To assess knowledge acquisition and recall, participants will be shown up to 10 pre-specified webpages within their site of randomization that contain information that answers up to 10 discrete questions about chlorthalidone. Participants will answer up to 10 corresponding assessment questions immediately after viewing the information. The knowledge score will be the percentage of correct responses. The RA's will evaluate knowledge retention by asking the same assessment questions over the phone one week later. User experience, trust, and participant decision-making will be assessed through a survey and through a short semi structured interview. The investigators will also collect information on health literacy via the REALM-SF health literacy questionnaire as well as demographic information including age, level of education, race/ethnicity, prior Internet use, and access to the Internet.

To assess question prioritization/availability on PALS/WebMD, the investigators will show participants a list of up to 40 questions and ask them to chose those most important to them. The investigators will search for the answers to the highest prioritized questions to determine availability on PALS/WebMD.

Surveys and knowledge scores will be administered via Qualtrics. Participants will be compensated with a $25 ClinCard after completing the study visit.

Study Type

Interventional

Enrollment (Actual)

118

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10021
        • Weill Cornell Internal Medicine Associates

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Weill Cornell Internal Medicine Associates (WCIMA) patients with hypertension who have been prescribed any antihypertensive medicine except chlorthalidone.
  • Patients who meet the criteria above and are English speaking and without cognitive impairment or other medical condition that would impair or preclude their ability to participate (such as a serious medical condition).

Exclusion Criteria:

  • WCIMA patients without hypertension
  • WCIMA patients with hypertension who have not been prescribed antihypertensive medicine
  • Patients who are non-English speaking
  • Patients with cognitive impairment or other medical condition that would impair or preclude their ability to participate (such as a serious medical condition).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PALS
Participants will view materials about the antihypertensive, chlorthalidone on the Patient Activated Learning System (PALS).
PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
Active Comparator: WedMD
Participants will view materials about the antihypertensive, chlorthalidone on WebMD.
WebMD is an internet based health information source.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knowledge acquisition
Time Frame: Immediate
Subjects will be asked questions about the materials they viewed.
Immediate

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recall
Time Frame: 1 week
Subjects will be asked questions about the materials they viewed.
1 week
User experience
Time Frame: Immediate
Participants will be asked about user experience including trust, usefulness, comprehensibility, and adequacy of the information, attractiveness of the site, and level of engagement of materials.
Immediate
Decision making
Time Frame: Immediate
Participants will be asked if they have sufficient information to make hypothetical decisions about taking chlorthalidone.
Immediate

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Amanda S Carmel, MD, Weill Medical College of Cornell University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 15, 2017

Primary Completion (Actual)

December 31, 2017

Study Completion (Actual)

December 31, 2017

Study Registration Dates

First Submitted

March 15, 2017

First Submitted That Met QC Criteria

May 15, 2017

First Posted (Actual)

May 17, 2017

Study Record Updates

Last Update Posted (Actual)

April 23, 2019

Last Update Submitted That Met QC Criteria

April 22, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 1610017672

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patient Education

Clinical Trials on PALS

3
Subscribe